May 14, 2020 10:56 AM EDT
News Briefing

ADC up­sizes IPO of­fer­ing in search of a $175M-plus haul; No­vo presents en­cour­ag­ing GLP-1 da­ta from obe­si­ty study

John Carroll

Editor & Founder

Natalie Grover

Reporter

→ Swiss biotech ADC Ther­a­peu­tics is up­siz­ing its IPO of­fer­ing by about 3 mil­lion shares. The lat­est up­date in­cludes new plans to sell 10 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Sage sues Bio­gen days af­ter $469M buy­out of­fer

FDA ap­proves As­traZeneca and Dai­ichi Sankyo’s ADC for breast can­cer de­spite lack of sur­vival ben­e­fit

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

Kathy High leads GV, ARCH-backed eye dis­ease biotech; Arv­inas com­mer­cial ex­ec steps down

No­vo claims high-dose Phase 3 We­govy win but sales im­pact might be mut­ed

Roche's car­diometa­bol­ic chief warns against weight loss 'ob­ses­sion' with GLP-1s

A service from the Financial Times